News & Events
Clinical Trials Found
16 Mar 2022 08:13:00
Molecule: LP-108, is a Highly Potent and Selective Bcl-2 Inhibitor
Status: Recruiting
US Trail Link | China Trial Link
Molecule: LP-118, is a Novel, Highly Potent, Oral, Bcl-2 Inhibitor Overcoming the Bcl-2 Resistant Mutations
Status: Recruiting
Molecule: LP-168, is the New Generation Inhibitor of a Clinically Validated Pathway, Targeting both WT and Multiple Resistance Mutations by Different Binding Mechanism
Status: Recruiting